Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Date:3/11/2008

publication in Clinical Cancer Research highlighting bavituximab's ability to target tumor blood vessels with excellent specificity, and the acceptance last week of an abstract discussing patient data from the Cotara dosimetry trial for presentation at the 2008 ASCO Annual Meeting. We anticipate additional high profile scientific publications and presentations in the coming months while we continue making good progress in advancing our trio of Phase II bavituximab cancer trials, the two ongoing Cotara clinical trials and the trial of bavituximab in HCV patients co-infected with HIV. We look forward to a steady flow of news from these multiple activities in the coming months."

Recent Highlights

Bavituximab Anti-Cancer Program: The company launched the Phase II cancer clinical program for bavituximab during the quarter and achieved a number of other clinical and preclinical advancements.
-- Initiated patient dosing in a Phase II combination therapy trial of

bavituximab and docetaxel in patients with advanced breast cancer

within 14 days of study initiation.

-- Received regulatory approval to begin two additional Phase II

bavituximab combination therapy trials -- one in combination with

carboplatin and paclitaxel in patients with advanced breast cancer and

another in combination with carboplatin plus paclitaxel in patients

with non-small cell lung cancer (NSCLC). Both trials are preparing to

begin enrolling patients shortly.

-- A bavituximab cancer investigator presented data at a leading

scientific meeting on anti-angiogenic agents -- the 10th Annual

International Symposium on Anti-Angiogenic Agents (Angio 2008) --

highlighting the positive clinical experience to date with

bavituximab.

-- A preclinical study published in Clinical Cancer Research confirmed

bavituximab's ability to target tumor blood ves
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
2. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
3. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
6. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
7. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
10. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
11. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Faso (PRWEB) July 10, 2014 ... today have access to an additional family planning ... access to contraception at all levels of the ... lower-dose formulation of a widely used contraceptive—Pfizer’s Depo-Provera® ... , Burkina Faso is the first of four ...
(Date:7/10/2014)... Boston, Mass. (PRWEB) July 10, 2014 ... , today announced that Alan Swahn, a former vice ... Terascala’s executive team as vice president of marketing. Terascala’s ... from Dell and NetApp create the highest performance and ... has been appointed to guide Terascala’s channel expansion and ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2
... of dementia ... and participation in clinical trials., Silicon Valley,s Conway, Campbell ... Internet to Transform Medical Research and Philanthropic Outreach, ... of,California, San Francisco (UCSF) today launched a comprehensive Internet,video ...
... Life Sciences Inc.,(TSX: PLI) ("ProMetic") today presented ... trial in patients with chemotherapy-induced,anemia ("CIA") at ... Association,held in Copenhagen, Denmark this week., ... presented data on,PBI-1402 in a poster entitled ...
... VANCOUVER, June 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ... pharmaceutical and,medical device company, today announced the market ... available immediately for distribution,and sale in the U.S. ... made from a rapidly resorbing,polymer, is intended primarily ...
Cached Biology Technology:UCSF and YouTube Launch Channel Dedicated to Educating the Public About Neurodegenerative Diseases 2UCSF and YouTube Launch Channel Dedicated to Educating the Public About Neurodegenerative Diseases 3Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 2Positive clinical data for PBI-1402 presented at the Annual Congress of the European Hematology Association 3Angiotech announces market launch of Quill(TM) SRS MONODERM(TM) 2Angiotech announces market launch of Quill(TM) SRS MONODERM(TM) 3Angiotech announces market launch of Quill(TM) SRS MONODERM(TM) 4
(Date:7/11/2014)... started near the City of Entiat on Tuesday, July ... fire quickly grew to over 1,000 acres by evening. ... is under investigation by the Washington Department of Natural ... local resources in developing fire control strategies and tactics. ... State Department of Natural Resources, (WA DNR), Bureau of ...
(Date:7/11/2014)... scientists have set a "mouse TRAP" to capture the ... recent study published in the Journal of Clinical ... technique called TRAP to extract cellular and genetic information ... scientists at the Rockefeller Institute for Medical Research in ... protein-making machinery, or ribosomes, of the cell type of ...
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2
... almost 30 years, researchers have sought to identify a ... during photosynthesis. A team at Ludwig-Maximilians-Universitt (LMU) in Munich ... to be an old acquaintance. Photosynthesis sustains ... molecular oxygen that higher organisms depend on. The process ...
... Marine resource managers often gauge the health of species ... relationships in the Bering Sea found that it isn,t the ... how densely they are aggregated. It,s more than searching ... balance how much energy they expend in searching for food ...
... make animals, well, brainier, but that boost in brain size ... evidence reported on January 3rd in Current Biology , ... for large and small brain sizes. The findings lend ... ability do go together, a topic that has been a ...
Cached Biology News:Photosynthesis: The last link in the chain 2Bering Sea study finds prey density more important to predators than biomass 2Bering Sea study finds prey density more important to predators than biomass 3Big brains are pricey, guppy study shows 2
This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Phospho-MEF2A(Thr312)...
Biology Products: